Advertisement
top banner image  

topleft corner image     top right corner image
 
ACCF/AHA Clinical Guidelines and Statements

CME logo image
bullet
bullet
bullet
bullet

JACC Homepage JACC Imaging Homepage
Still not a subscriber to JACC Imaging or JACC Interventions?

take action
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet

acc links
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet

jacc interventions image
bullet
bullet
bullet
bullet

     top nav image

     

J Am Coll Cardiol Intv, 2009; 2:767-775, doi:10.1016/j.jcin.2009.05.016
© 2009 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Novack, V.
Right arrow Articles by Cohen, D. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Novack, V.
Right arrow Articles by Cohen, D. J.
Related Collections
Right arrowRelated Article

In-Hospital and 1-Year Outcomes Among Unselected Percutaneous Coronary Intervention Patients Treated With Either Sirolimus- or Paclitaxel-Eluting Stents

Results From the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) Registry

Victor Novack, MD, PhD*, Donald Cutlip, MD*,{dagger}, Neal Kleiman, MD{ddagger}, Michael Pencina, PhD*, Laura Mauri, MD, MSc*,§, Chen-Hsing Yen, MS*, Peter Berger, MD||, Steven Goldberg, MD, Mirle Kellett, MD#, Ronald Waksman, MD**, Mun Hong, MD{dagger}{dagger}, Albert E. Raizner, MD{ddagger}, David J. Cohen, MD, MSc{ddagger}{ddagger},*

* Harvard Clinical Research Institute, Boston, Massachusetts
{dagger} Beth Israel Deaconess Medical Center, Boston, Massachusetts
{ddagger} The Methodist DeBakey Heart Center, Houston, Texas
§ Brigham Women's Hospital, Boston, Massachusetts
|| Geisinger Clinic, Danville, Pennsylvania
University of Washington Medical Center, Seattle, Washington
# Maine Medical Center, Portland, Maine
** Washington Hospital Center, Washington, DC
{dagger}{dagger} St. Luke's-Roosevelt Hospital Center, New York, New York
{ddagger}{ddagger} Saint-Luke's Mid America Heart Institute, Kansas City, Missouri


Figure 1
View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 1 Proportion of SES Use (Among All Drug-Eluting Stent Procedures) in the 47 EVENT Registry Hospitals

SES = sirolimus-eluting stent.

 

Figure 2
View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 2 Kaplan-Meier Survival Curves

Kaplan-Meier survival curves for time to cardiac death or myocardial infarction (MI) (A), time to definite or probable stent thrombosis (B), and time to target lesion revascularization (C). PES = paclitaxel-eluting stent(s); SES = sirolimus-eluting stent(s).

 

Figure 3
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 3 Cox Proportional Hazard Regression Derived Hazard Ratios

Cox proportional hazard regression derived hazard ratios comparing SES versus PES for the end points of cardiac death or MI (A), target lesion revascularization (B), and stent thrombosis (C) at 12 months (with 95% confidence interval). Hazard ratios are derived from risk-adjustment models with sequential inclusion of baseline clinical characteristics, lesion characteristics, procedural characteristics, and site characteristics as described in the Methods section. Abbreviations as in Figure 2.

 

Figure 4
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 4 Adjusted Hazard Ratios (SES vs. PES) for Cardiac Death or MI and TLR

Adjusted hazard ratios (SES vs. PES) for cardiac death or MI (A) and TLR (B) among pre-specified subgroups. ACS = acute coronary syndrome; DM = diabetes mellitus; TLR = target lesion revascularization; other abbreviations as in Figure 2.

 




Advertisement
 
   
 
home link current link search link archive link topics link cardiology careers link